Tripling Your Likelihood of Approval (LOA) with Selection Biomarkers
In case you missed it, view the video recording of our recent webinar to learn:
- The Likelihood of Approval (LOA) methodology for analyzing clinical trial success rates
- How using biomarkers as patient selection criteria triple the LOA of clinical trials
- LOA for select therapeutic areas
Co-Founder and CEO
John is passionate about accelerating basic research discoveries into healthcare advancements. John became aware of the need for a resource like BiomarkerBase during his 7 years running MitoSciences Inc. (now part of Abcam plc). Trying to identify the next targets for new monoclonal antibodies and drug screening assays was a continuing challenge, despite the availability of lots of relevant information in the public domain.
John writes actively on topics related to biomarkers and personalized medicine at our blog Biomarker Trends. John also supports the biotech industry as a board member for the Oregon Bioscience Association and the Professional Science Masters Program at Oregon State University.